# **Exploring the Certainty of Evidence Over Time in a Living Systematic Review**

María-José Oliveros<sup>1-2</sup>, Sara Ibrahim<sup>1</sup>, Pamela Serrón<sup>2</sup>, Gordon Guyatt<sup>1</sup>, Nancy Santesso<sup>1</sup>, Romina Brignardello-Petersen<sup>1</sup> 1. Health Research Methods, Evidence, and Impact (HEI); 2. Departmento de Ciencias de la Rehabilitación, Universidad de La Frontera, Chile

**CONTACT INFORMATION:** oliverom@mcmaster.ca

## BACKGROUND

Evidence-based practice states that effect estimates are closer to the truth when based on higher certainty evidence (CoE). Therefore, even if there is new evidence, the best estimates of treatment effects are less likely to change if they are based on high or moderate CoE, than if they are based on low or very low CoE.

### **OBJECTIVE**

To describe how the CoE and the direction of effect estimates evolve as evidence accumulates in a living systematic review and network meta-analysis (LSRNMA).

31%



In total, 151 observations reported data for consecutive time points for the same outcome and comparison.

### **1. TRENDS IN COE FOR MORTALITY FOR DIFFERENT DRUGS ACROSS PUBLICATIONS**

To see the label legends, please scan the QR code at the bottom



OUTCOME	v0-v1 Number obs (%)	v1-v2 Number obs (%)	v2-v3 Number obs (%)	v3-v4 Number obs (%)
Mechanical Ventilation	2(6.5%)	4(12.9%)	8(25.8%)	17(54.8%)
Duration hospitalization	1 (8.3%)	3 (25%)	8(66.7%)	0(0%)
Duration of MV	0(0%)	0(0%)	2 (40%)	3(60%)
Time to symptom resolution	2 (9.5%)	3(14.3%)	7(33.3%)	9(42.9%)
Viral clearance	3(27.3%)	3(27.3%)	5(45.5)	0(0%)
Admission hospital	0(0%)	1(10%)	1(10%)	8(80%)
Adverse events	2(11.8%)	2(11.8%)	2(11.8%)	11(64.7%)
Mortality	5(11.4%)	7(15.91%)	11(25%)	21(47.7%)
TOTAL	15(9.9%)	23(15.2)	44(29.1%)	69(45.7%)

2. FREQUENCY OF CONCORDANCE AND DISCORDANCE IN COE FOR **ALL OUTCOMES AT TWO CONSECUTIVE TIMEPOINTS** 

**3. BEHAVIOUR OF THE DIRECTION OF INTERVENTION EFFECTS AT TWO TIME POINTS ACCORDING TO THE INITIAL COE** 





What happens to the direction of the intervention effect in the next timepoint according to the

initial CoE?

Remained as Unknown

**Remained as No Effect** 

**Remained as Beneficial** 

Unknown

Changed from Beneficial to

64%

30%

5%

10%

Changed from Beneficial to No Effect

Changed from No Effect to Unknow

Changed from No Effect to Beneficial

Changed from No Effect to Harmful

2%\_\_\_

61%

13%

5%

E2	MODERAT	<b>E</b> 4.3%	13.1%	65.0%	0.0%			
2 F	LOW	32.9%	62.3%	15.0%	0.0%			
	VERYLOV	N 61.4%	23.0%	10.0%	0.0%	Wł		
	_	VERYLOW	LOW	MODERATE	HIGH			
TIME 1								
METHODS								
We used <u>direct estimates</u> and <u>GRADE assessments</u> from five iterations of our LSRNMA of COVID-19 treatments.								
	/.0	<b>V.1</b>	V	.2	<b>V.3</b>	V.4		
Ori	ginal							

As evidence accumulates, CoE more often remained stable or increases.

#### In this sample:

Changed from Unknown to Beneficial

Changed from Unknown to No Effect

Changed from Unknown to Harmful

When CoE is moderate, the direction of the effect remained  $\bullet$ 

CONCLUSIONS

publication				
20-07-2020*	10-08-2020*	12-11-2020*	12-11-2020*	03-12-2021*

Update 2

\*Search until (date)

Update 4

Data included comparisons between drug treatments and standard care/placebo with results from at least two iterations (two time points)

Mortality

Mechanical ventilation

Update 1

- Adverse events
- Hospital admission
- Viral clearance
- Duration of mechanical ventilation
- Hospital length of stay

Update 3

• Time to symptom resolution.



- When CoE is low, the intervention effect remains stable in **69% of cases**, with 64% consistently showing "no effect."
- accumulating evidence, interventions initially Despite classified as very low CoE are likely to remain as such, leaving the effect unknown.









Would You Like to Share Your **Feedback or Comments?** 



BIBLIOGRAPGY: Siemieniuk RA, et al. Drug treatments for covid-**19: living systematic review and network meta-analysis.** PMID: 32732190; PMCID: PMC7390912.